Compositions comprising pectin and ascorbic acid
    63.
    发明授权
    Compositions comprising pectin and ascorbic acid 有权
    包含果胶和抗坏血酸的组合物

    公开(公告)号:US08242096B2

    公开(公告)日:2012-08-14

    申请号:US12378306

    申请日:2009-02-13

    IPC分类号: A01N61/00 A01N51/00

    CPC分类号: A61K9/205 A61K31/375

    摘要: Ascorbic acid compositions in the form of a powder and/or granules contain as principle components L-ascorbic acid and/or a pharmaceutically acceptable salt thereof, and a high molecular (300 kDalton or higher) pectin. The compositions are compressible into tablets with improved mechanical strength and hardness.

    摘要翻译: 粉末形式和/或颗粒形式的抗坏血酸组合物含有作为主要成分的L-抗坏血酸和/或其药学上可接受的盐和高分子量(300kDa以上)的果胶。 组合物可压缩成具有改善的机械强度和硬度的片剂。

    Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
    68.
    发明授权
    Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof 有权
    鉴定多巴胺激动剂治疗反应者和治疗其代谢状况的方法

    公开(公告)号:US08137992B2

    公开(公告)日:2012-03-20

    申请号:US12931859

    申请日:2011-02-11

    摘要: The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites:dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has blood pressure of greater than about 135/85 mm Hg. The present invention is also directed to treating identified patients with dopamine agonist therapy.

    摘要翻译: 本发明涉及一种通过多巴胺激动剂治疗来鉴定待治疗患者的方法,包括以下步骤:从去甲肾上腺素(NE),去甲肾上腺素代谢物(NE代谢物),多巴胺,多巴胺代谢物的浓度分析来自所述患者的血浆或尿样品 (a)NE代谢产物,(b)NE / NE代谢产物:多巴胺/多巴胺代谢产物,(c)NE和5-羟色胺,(d)NE / NE代谢产物和 5-羟色胺,(e)NE和5-羟色胺代谢物,(f)NE / NE代谢物和5-羟色胺代谢物,或(g)NE比正常水平高大约30% 或多巴胺/多巴胺代谢物低于正常值的约30% 或空腹甘油三酸酯大于约150mg / dl,和/或所述患者具有大于约135/85mm Hg的血压。 本发明还涉及治疗多巴胺激动剂治疗的鉴定患者。

    MICROFLUIDIC CHEMOSTAT
    70.
    发明申请
    MICROFLUIDIC CHEMOSTAT 有权
    微血管化学

    公开(公告)号:US20120065277A1

    公开(公告)日:2012-03-15

    申请号:US13197654

    申请日:2011-08-03

    IPC分类号: A01N61/00 A01P1/00 C12M1/00

    摘要: A chemostat is described that includes a growth chamber having a plurality of compartments. Each of the compartments may be fluidly isolated from the rest of the growth chamber by one or more actuatable valves. The chemostat may also include a nutrient supply-line to supply growth medium to the growth chamber, and an output port to remove fluids from the growth chamber. Also, a method of preventing biofilm formation in a growth chamber of a chemostat is described. The method may include the steps of adding a lysis agent to a isolated portion of the growth chamber, and reuniting the isolated portion with the rest of the growth chamber.

    摘要翻译: 描述了一种恒温器,其包括具有多个室的生长室。 每个隔室可以通过一个或多个可致动阀与生长室的其余部分流体隔离。 恒化器还可以包括向生长室供应生长培养基的营养供应线以及从生长室去除流体的输出端口。 另外,描述了在恒化器的生长室中防止生物膜形成的方法。 该方法可以包括以下步骤:将裂解剂加入生长室的分离部分,并将分离的部分与生长室的其余部分重新连接。